Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 468.29 USD -0.2% Market Closed
Market Cap: 120.6B USD
Have any thoughts about
Vertex Pharmaceuticals Inc?
Write Note

EV/EBIT
Enterprise Value to EBIT

26.4
Current
20.2
Median
4.3
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
26.4
=
Enterprise Value
113B USD
/
EBIT
4.3B USD
All Countries
Close
EBIT Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average EV/EBIT: 22.5
26.4
45%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -215 386.8 N/A
US
Abbvie Inc
NYSE:ABBV
23.3
90%
US
Amgen Inc
NASDAQ:AMGN
31.3
90%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
32%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -504.8 N/A
AU
CSL Ltd
ASX:CSL
25.1
54%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.6
42%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -77.3 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -164.7 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
170.8
2-Years Forward
EV/EBIT
20.3
3-Years Forward
EV/EBIT
17.9

See Also

Discover More